Application of clinical and molecular profiling data to improve patient outcomes in psoriatic arthritis

Fitzgerald O, Behrens F, Barton A, Bertheusen H, Boutouyrie-Dumont B, Coates L, Davies O, De Wit M, Fagni F, Goodyear CS, Gurke R, Hahnefeld L, Huppertz C, Ioannidis V, Ibberson M, Katz A, Klippstein M, Koehm M, Korish S, Mackay S, Martin DA, O'Sullivan D, Patel K, Rüping S, Schett G, Scholich K, Schwenk JM, Siebert S, Simon D, Vivekanantham A, Pennington SR (2023)

Publication Language: English

Publication Type: Journal article, Review article

Publication year: 2023

Journal

Book Volume: 15

DOI: 10.1177/1759720X231192315

Abstract

Achieving a good outcome for a person with Psoriatic Arthritis (PsA) is made difficult by late diagnosis, heterogenous clinical disease expression and in many cases, failure to adequately suppress inflammatory disease features. Single-centre studies have certainly contributed to our understanding of disease pathogenesis, but to adequately address the major areas of unmet need, multi-partner, collaborative research programmes are now required. HIPPOCRATES is a 5-year, Innovative Medicines Initiative (IMI) programme which includes 17 European academic centres experienced in PsA research, 5 pharmaceutical industry partners, 3 small-/medium-sized industry partners and 2 patient-representative organizations. In this review, the ambitious programme of work to be undertaken by HIPPOCRATES is outlined and common approaches and challenges are identified. It is expected that, when completed, the results will ultimately allow for changes in the approaches to diagnosing, managing and treating PsA allowing for better short-term and long-term outcomes.

Authors with CRIS profile

Involved external institutions

Universitätsklinikum Frankfurt am Main (KGU) Germany (DE) University of Manchester United Kingdom (GB) University College Dublin (UCD) Ireland (IE) Novartis AG Switzerland (CH) GRAPPA Patient Research Partners (PRP) Network United States (USA) (US) Fraunhofer-Institut für Translationale Medizin und Pharmakologie (ITMP) / Fraunhofer Institute for Translational Medicine and Pharmacology Germany (DE) University of Oxford United Kingdom (GB) University of Glasgow United Kingdom (GB) SIB Swiss Institute of Bioinformatics / SIB Institut Suisse de Bioinformatique / SIB Istituto Svizzero di Bioinformatica / SIB Schweizerisches Institut für Bioinformatik Switzerland (CH) UCB Pharma Ltd United Kingdom (GB) Fraunhofer-Institut für Intelligente Analyse- und Informationssysteme IAIS / Fraunhofer Institute for Intelligent Analysis and Information Systems IAIS Germany (DE) Fraunhofer Cluster of Excellence Immune-Mediated Diseases CIMD Germany (DE) Royal Institute of Technology / Kungliga Tekniska Högskolan (KTH) Sweden (SE) Bristol-Myers Squibb United States (USA) (US) Pfizer, Inc. United States (USA) (US) Goethe-Universität Frankfurt am Main Germany (DE)

How to cite

APA:

Fitzgerald, O., Behrens, F., Barton, A., Bertheusen, H., Boutouyrie-Dumont, B., Coates, L.,... Pennington, S.R. (2023). Application of clinical and molecular profiling data to improve patient outcomes in psoriatic arthritis. Therapeutic Advances in Musculoskeletal Disease, 15. https://dx.doi.org/10.1177/1759720X231192315

MLA:

Fitzgerald, Oliver, et al. "Application of clinical and molecular profiling data to improve patient outcomes in psoriatic arthritis." Therapeutic Advances in Musculoskeletal Disease 15 (2023).

BibTeX: Download